We are excited to announce the 14th annual Harvard Psychopharmacology 2025: A Master Class, a specialized two-day event designed for practicing clinicians, clinical researchers, and trainees in psychiatry. This advanced course focuses on enhancing the clinical expertise of participants in treating difficult and treatment-resistant psychiatric patients. With an emphasis on the latest advances in psychopharmacology, the Master Class will explore emerging treatments, genetic tests, blood level measurements, and novel drug combinations that can inform clinical practice.
Throughout the course, participants will gain insights into the importance of building a strong therapeutic alliance when prescribing psychotropic medications. There will also be discussions on cutting-edge neurobiological research that will influence clinical practice, enhancing participants’ ability to provide optimal care for their patients.
The Master Class provides a unique opportunity for direct interaction with presenters, allowing for in-depth discussions and the sharing of valuable clinical insights.
* Date of Original Release: March 28-29, 2025
LEARNING OBJECTIVES
At the completion of this course, you should be able to:
- Evaluate the effects of neurotransmitters, neurocircuits, and genes on psychotropic drug treatment.
- Describe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode.
- Outline the emerging theories and treatments of bipolar disorder, depression, treatment resistant depression, bipolar depression, stress, and anxiety, PTSD, and neuropsychiatric disorders.
- Discuss the role of psychopharmacology in the management of depression and bipolar disorder in childhood and adolescence.
- Identify the benefits and risks of ketamine and psychedelics, including use for PTSD.
- Discuss the role of psychotropic medications in women’s mental health with an emphasis on PMS, pregnancy, nursing, and the postpartum period.
- Explain the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates, and cannabis.
- Give examples of the latest advances and problems associated with treatment approaches in the geriatric populations.
HARVARD PSYCHOPHARMACOLOGY 2025: A MASTER CLASS
